Friday February 24th 2017: Abbott Laboratories, ABT is in the exchange NYSE and its industry is Medical Appliances & Equipment in the sector of Healthcare. Based in USA, Abbott Laboratories, ABT has a market cap of 84.48 B. Since its IPO date on the 04/06/1983, Abbott Laboratories, ABT performance year to date is 27.34%. Today Abbott Laboratories, ABT has gained 0.00%, with a current price of 48.91.
Ownership of the company is 0.70% for insider ownership while institutional ownership is 73.40%. The management of the company have seen the company have a payout ratio of 107.00%. Return of assets are at 3.00%, with return on investment at 6.70%.
In terms of debt levels and profit levels, Abbott Laboratories, ABT is seeing a long-term debt/equity of 0.76. While Total debt/equity is 0.76. With a profit margin of 6.70%, this is combined with a gross margin of 55.50%, and operating margin of 11.00%. Abbott Laboratories ability to meet debt levels, with a current ratio of 2.9, while the quick ratio is 2.3.
For the last year Abbott Laboratories, ABT has seen a EPS growth of -58.60%. A performance for the year of 15.68%. The 52-week high is -1.37%, and the 52-week low is 30.85%. The average volume for Abbott Laboratories, ABT is 0.
With a target price of 51.38, can Abbott Laboratories, ABT reach this target? Looking at the value indicators of Abbott Laboratories, ABT. Abbott Laboratories has a P/E of 54.28 and a forward P/E of 17.75. Perhaps the more useful indicator than P/E, is PEG which has a value of 4.91. Abbott Laboratories also has a P/S and a P/B of 3.79 and 2.69 respectively. For P/cash, Abbott Laboratories has a value of 9.54, while it is 76.39 for P/free cash flow.
At the current price of 48.91, Abbott Laboratories has a dividend yield of 2.17%. We see a return on equity of 6.40%.
Looking more long-term Abbott Laboratories, is projected to get an EPS growth for the next five years of 11.06%. In the short-term an EPS growth of 11.76% in the next year is forecasted. This is after a EPS growth of -58.60% for this year and for the last five years a 0.00% growth has been seen.